A Review on miRNAs in Enteric Bacteria-mediated Host Pathophysiology: Mechanisms and Implications

Ahmed S. Doghish, Ola Elazazy, Hend H. Mohamed, Reda M. Mansour, Aml Ghanem, Ahmed H. I. Faraag, Mohammed S. Elballal, Mahmoud A. Elrebehy, Ahmed E. Elesawy, Sherif S. Abdel Mageed, Sameh Saber, Yara A. Nassar, Ahmed I. Abulsoud, Mustafa Ahmed Abdel-Reheim, Alaa S. Elawady, Mohamed A. Ali, Mohamed Salah Basiouny, Mohamed Hemdan, Radwa H. Lutfy, Farah A. Awad, Salma A. El-Sayed, Mohamed M. Ashour, Gharieb S. El-Sayyad, Osama A. Mohammed

Info

Journal
Wiley's

Journal of Biochemical and Molecular Toxicology

Publishing Date

February 2025

Volume

39

Issue

2

Abstract

Recently, many studies focused on the billions of native bacteria found inside and all over the human body, commonly known as the microbiota, and its interactions with the eukaryotic host. One of the niches for such microbiota is the gastrointestinal tract (GIT), which harbors hundreds to thousands of bacterial species commonly known as enteric bacteria. Changes in the enteric bacterial populations were linked to various pathologies such as irritable bowel syndrome and obesity. The gut microbiome could affect the health status of individuals. MicroRNAs (miRNAs) are one of the extensively studied small-sized noncoding RNAs (ncRNAs) over the past decade to explore their multiple roles in health and disease. It was proven that miRNAs circulate in almost all body fluids and tissues, showing signature patterns of dysregulation associated with pathologies. Both cellular and circulating miRNAs participate in the posttranscriptional regulation of genes and are considered the potential key regulators of genes and participate in cellular communication. This manuscript explores the unique interplay between miRNAs and enteric bacteria in the gastrointestinal tract, emphasizing their dual role in shaping host-microbiota dynamics. It delves into the molecular mechanisms by which miRNAs influence bacterial colonization and host immune responses, linking these findings to gut-related diseases. The review highlights innovative therapeutic and diagnostic opportunities, offering insights for targeted treatments of dysbiosis-associated pathologies.

DOI